Efficacy and Safety of Tirzepatide Versus Placebo in Adolescents With Obesity and Weight-Related Comorbidities: A Randomized, Double-Blind Trial

The primary objective of the study is to evaluate the efficacy of **tirzepatide** at its maximum tolerated dose (MTD) compared to placebo in achieving a reduction in body mass index (BMI) among adolescents with **obesity**. This is clinically relevant as obesity in adolescents is associated with significant health risks and a reduction in BMI can lead to improved health outcomes. Additionally, the study aims to demonstrate the superiority of tirzepatide MTD over placebo in improving weight-related comorbidities, which are common in adolescents with obesity and can lead to further health complications if not addressed.

The clinical trial involves a total of **255 participants** diagnosed with **obesity**. The study population comprises both male and female subjects aged between **12 to 17 years**. Participants were selected based on their **Body Mass Index (BMI)**, specifically those with a BMI equal to or above the 95th percentile for their age and sex according to the CDC-NCHS 2022 guidelines. The trial includes a vulnerable population, indicating a careful consideration of ethical standards in participant selection. The study does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not provided additional information regarding the general health status of the participants beyond the specified inclusion criteria.

The clinical trial is designed to evaluate the **efficacy** and safety of **tirzepatide** in adolescents with **obesity** and weight-related comorbidities. This study is a randomized, double-blind, placebo-controlled trial, which aims to demonstrate that tirzepatide is superior to placebo in achieving a reduction in body mass index (BMI) and improving weight-related comorbidities. The trial is expected to commence recruitment on September 1, 2024, and conclude by April 2, 2027, with a maximum treatment period of 18 months for each participant.

Participants will be randomly assigned to receive either tirzepatide or a placebo, both administered as a **solution for injection** via the subcutaneous route. The study will include several key visits: an initial screening visit to confirm eligibility, regular follow-up visits to monitor progress and safety, and an end-of-study visit to assess the primary and secondary endpoints. The primary endpoints include the percent change from baseline in BMI and a composite endpoint related to weight-related comorbidities. Participants are expected to be involved in the study for the full duration unless specific conditions necessitate early termination, such as adverse events or withdrawal of consent.

Inclusion criteria require participants to be aged 12 to 17 years with a BMI at or above the 95th percentile for their age and sex. The trial will exclude individuals who do not meet these criteria or have conditions that could interfere with the study outcomes. The study's design ensures that neither the participants nor the investigators will know which treatment the participants are receiving, maintaining the integrity of the double-blind methodology. The trial will be conducted in accordance with regulatory standards to ensure the safety and well-being of all participants.

The clinical trial involves the administration of **Tirzepatide**, an investigational medication developed by Eli Lilly and Company. Tirzepatide is provided in the form of a **solution for injection** and is administered via the **subcutaneous route**. The active substance, tirzepatide, is a protein of other origin. The pharmaceutical form is consistent across all doses, and the medication is identified by the sponsor product code LY3298176. The maximum treatment period for tirzepatide is 18 weeks, with the dosing schedule determined by the study protocol. Participant compliance with the dosing regimen is monitored throughout the trial to ensure adherence to the treatment plan.

In addition to the experimental medication, a **placebo** is utilized as a comparator in this double-blind, placebo-controlled trial. The placebo is designed to match the LY3298176 injection in appearance but does not contain the active substance. The placebo serves as a control to evaluate the efficacy and safety of tirzepatide in achieving body mass index (BMI) reduction and improving weight-related comorbidities in adolescents. The administration of the placebo follows the same subcutaneous route and schedule as the active treatment to maintain the study's blinding integrity.

The efficacy of **Tirzepatide** in the clinical trial titled "I8F-MC-GPIX: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents" will be assessed using specific primary endpoints. These endpoints include the percent change from baseline in Body Mass Index (BMI) and a composite endpoint that evaluates normalization or clinically significant improvement in at least two predefined weight-related comorbidities present at screening, without the development of a new predefined comorbidity or worsening of an existing one.

The trial aims to demonstrate that **Tirzepatide** at the maximum tolerated dose (MTD) is superior to placebo in achieving BMI reduction and improving weight-related comorbidities. The efficacy parameters will be measured and collected at various timepoints throughout the trial, although specific timepoints are not detailed in the provided data. The trial is designed as a randomized, double-blind, placebo-controlled study, ensuring rigorous assessment of the treatment's efficacy.